Azienda Ospedaliero-Universitaria di Cagliari
SISTEMA SANITARIO DELLA SARDEGNA

Approvazione dello schema di Accordo di riservatezza relativo agli studi clinici dal titolo: “A Randomized, Open-label Phase 3 Study of Amivantamab + mFOLFOX6 or FOLFIRI Versus Cetuximab + mFOLFOX6 or FOLFIRI as First-line Treatment In Participants with RAS/RAF Wild-Type Unresectable or Metastatic Left-sided Colorectal Cancer (61186372COR3001)” e “A Randomized, Open-label Phase 3 Study of Amivantamab + FOLFIRI Versus Cetuximab/Bevacizumab + FOLFIRI in Participants with RAS/RAF Wild-Type Recurrent Metastatic Colorectal Cancer Who Have Received or Intolerant to Prior Chemotherapy. (61186372COR3002)”. Sperimentatore Responsabile degli Studi: Prof. Mario Scartozzi – SC Oncologia Medica”.